(TheNewswire)
Winnipeg – TheNewswire- June 20, 2024 - Cytophage Technologies Ltd.( TSXV:CYTO ) (“ Cytophage ” or the “Company”), the only publicly traded phage companythat is focused on bacteriophage solutions for both animal health andhuman health, announces that it has signed of a Letter of Intent (LOI)with a leading Pan-Asian industrial agrifood company headquartered inSingapore. The LOI outlines acollaboration pathway between Cytophage and this company that operatesin six countries and derives approximately 80% of itsmulti-billion-dollar revenue from poultry operations. “Fullyintegrated poultry producers provide multifaceted opportunities forphage products – from eggs to feed to the chickens – creating anexciting environment in which to have our phage products improveproduction numbers by decreasing bacterial loads”, commentedCytophage CEO Dr. Steven Theriault. Cytophage anticipates conductingtrials with this commercial partner in Q4 of 2024.
Cytophage continues to collaborate with itsdistribution partner in Bangladesh, recently introducing itsinnovative lyophilized tablet designed to replace the traditionalliquid form commonly used in phage therapy. Thisnew form is expected to increase product shelf life and productreliability in tropical zones. The Companyrecognizes the importance of regionalizing phage products to addresslocal bacterial strains and environmental conditions in order tomaximize product adoption and meet customer needs.
Cytophage also announces the departure of Chief CommercializationOfficer (CCO) Michael Graham to pursue other endeavours. Therecently established Commercialization Committee of the Board,together with Dr. Theriault and the commercialization team, will workto drive initiatives forward and expand Cytophage’s market presence.“We will continue to explore and secure new commercializationopportunities in various marketplaces” stated Dr. Theriault. “Our thanks go to Michael for his contributions in advancing theCompany over the past six years and we wish him all the best for hisfuture.”
Cytophage will hold its Annual General Meeting (AGM) on June 25,2024. The AGM materials can be found on the Cytophage website at https://cytophage.com/investors/#agm Thismeeting will cover the business of the AGM. An investor presentationand update will be held at a later date.
For further information pleasecontact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies ( TSXV:CYTO ) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Committed to addressing theglobal challenge of antibiotic resistance, Cytophage advancesinnovative products that harness the power of bacteriophages to combatbacterial infections affecting human health, animal health, and foodsecurity.
Cautionary Statement onForward-Looking Information
This news release contains “forward-lookinginformation” and “forward-looking statements” (collectively,“forward-looking statements”) within the meaning of the applicableCanadian securities legislation. All statements, other than statementsof historical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are
described under the caption “Risk Factors” inCytophage’s Filing Statement dated January 30, 2024, which isavailable for view on SEDAR+ at www.sedarplus.ca. These risks includebut are not limited to, the risks associated with the bacteriophageindustry, such as operational risks in development or capitalexpenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2024 TheNewswire - All rights reserved.